Table 4 Immunomodulatory therapy applications to public and private insurance providers
Question | n (%) | 95 % CI |
|---|---|---|
How do you obtain immunomodulatory drugs or biologics for your patients? | ||
Request from a rheumatologist, dermatologist, gastroenterologist, or internist | 79 (54.5) | 0.46–0.62 |
Refer to an ophthalmologist who will prescribe or coordinate further care for patients with uveitis | 58 (40.0) | 0.32–0.48 |
Prescribe yourself | 8 (5.5) | 0.02–0.11 |
No response | 1 | |
Refer patients to a uveitis specialist | ||
Yes | 107 (73.3) | 0.65–0.80 |
No | 27 (18.5) | 0.13–0.26 |
I am a uveitis specialist | 12 (8.2) | 0.04–0.14 |
No response | 0 | |
Number of new applications made to the government per year for IMT coverage | ||
0–5 | 117 (93.6) | 0.88–0.97 |
6–10 | 5 (4.0) | 0.01–0.09 |
11–20 | 2 (1.6) | 0.002–0.06 |
21–30 | 1 (0.8) | 0.0002–0.04 |
>30 | 0 | |
No response | 21 | |
Number of co-applications for IMT made with rheumatologists or other physicians | ||
0–5 | 105 (89.0) | 0.69–0.84 |
6–10 | 10 (8.5) | 0.03–0.13 |
11–20 | 2 (1.7) | 0.002–0.05 |
21–30 | 0 | 0.00–0.03 |
>30 | 1 (0.8) | 0.002–0.04 |
No response | 28 | |
Percentage of respondent’s patients with their IMT successfully covered through government or provincial health plan | ||
<10 % | 71 (64.0) | 0.54–0.73 |
10–50 % | 32 (28.8) | 0.21–0.38 |
51–90 % | 5 (4.5) | 0.02–0.10 |
>91 % | 3 (2.7) | 0.006–0.08 |
No response | 35 | |
Percentage of respondent’s patients with their IMT successfully covered through private insurance | ||
<10 % | 61 (56.5) | 0.46–0.66 |
10–50 % | 29 (26.9) | 0.19–0.36 |
51–90 % | 10 (9.3) | 0.04–0.16 |
>91 % | 8 (7.4) | 0.03–0.14 |
No response | 38 | |
Class of IMT applied through the Exceptional Access Program | ||
Mycophenolate mofetil | 17 (25.0) | 0.11–0.28 |
Anti-TNF | 22 (32.4) | 0.16–0.35 |
Cyclosporine | 26 (38.2) | 0.20–0.39 |
Others | 25 (36.8) | 0.19–0.38 |
No response | ||